Literature DB >> 9220171

Time to earliest peak serum antibody response to influenza vaccine in the elderly.

P A Gross1, C Russo, S Dran, P Cataruozolo, G Munk, S C Lancey.   

Abstract

The earliest time at which serum antibody levels peak following administration of an influenza virus vaccine in elderly persons is not clearly defined. We compared the time intervals of 1 and 2 weeks after vaccination. A commercial trivalent vaccine containing the hemagglutinins of influenza viruses A/Texas/36/91 (H1N1), A/Johannesburg/33/94 (H3N2), and B/Harbin/7/94 was used. The hemagglutination inhibition (HAI) antibody titers at 1 week after vaccination were significantly lower than the HAI titers at 2 weeks postvaccination for all three vaccine components.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9220171      PMCID： PMC170557          DOI： 10.1128/cdli.4.4.491-492.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  5 in total

1.  A Hong Kong influenza immunity three years after immunization.

Authors:  H M Foy; M K Cooney; R McMahan
Journal:  JAMA       Date:  1973-11-12       Impact factor: 56.272

2.  Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.

Authors:  P A Gross; A E Davis
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

3.  Time to peak serum antibody response to influenza vaccine in the elderly.

Authors:  P A Gross; C Russo; M Teplitzky; S Dran; P Cataruozolo; G Munk
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

4.  Time to peak serum antibody response to influenza vaccine.

Authors:  S Rastogi; P A Gross; J Bonelli; S Dran; R A Levandowski; C Russo; M E Weksler; D Kaye; M Levison; E Abrutyn
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

5.  A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.

Authors:  P A Gross; F A Ennis; P F Gaerlan; L J Denson; C R Denning; D Schiffman
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226
  5 in total
  12 in total

1.  Efficacy of the influenza vaccine in patients with malignant lymphoma.

Authors:  Joseph J Mazza; Steven H Yale; Jodi R Arrowood; Cory E Reynolds; Ingrid Glurich; Po-Huang Chyou; James G Linneman; Kurt D Reed
Journal:  Clin Med Res       Date:  2005-11

2.  Timeliness of pediatric influenza vaccination compared with seasonal influenza activity in an urban community, 2004-2008.

Authors:  Annika M Hofstetter; Karthik Natarajan; Daniel Rabinowitz; Raquel Andres Martinez; David Vawdrey; Stephen Arpadi; Melissa S Stockwell
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

3.  An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States.

Authors:  Jerome I Tokars; Melissa A Rolfes; Ivo M Foppa; Carrie Reed
Journal:  Vaccine       Date:  2018-10-14       Impact factor: 3.641

4.  Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.

Authors:  Ramin Sedaghat Herati; Morgan A Reuter; Douglas V Dolfi; Kathleen D Mansfield; Htin Aung; Osama Z Badwan; Raj K Kurupati; Senthil Kannan; Hildegund Ertl; Kenneth E Schmader; Michael R Betts; David H Canaday; E John Wherry
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

5.  Pilot to evaluate the feasibility of measuring seasonal influenza vaccine effectiveness using surveillance platforms in Central-America, 2012.

Authors:  Nathalie El Omeiri; Eduardo Azziz-Baumgartner; Wilfrido Clará; Guiselle Guzmán-Saborío; Miguel Elas; Homer Mejía; Ida Berenice Molina; Yadira De Molto; Sara Mirza; Marc-Alain Widdowson; Alba María Ropero-Álvarez
Journal:  BMC Public Health       Date:  2015-07-17       Impact factor: 3.295

6.  Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations - Latin America, 2013.

Authors:  Nathalie El Omeiri; Eduardo Azziz-Baumgartner; Mark G Thompson; Wilfrido Clará; Mauricio Cerpa; Rakhee Palekar; Sara Mirza; Alba María Ropero-Álvarez
Journal:  Vaccine       Date:  2017-06-23       Impact factor: 3.641

7.  Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink.

Authors:  Georgina Nakafero; Matthew J Grainge; Puja R Myles; Christian D Mallen; Weiya Zhang; Michael Doherty; Jonathan S Nguyen-Van-Tam; Abhishek Abhishek
Journal:  Ann Rheum Dis       Date:  2019-04-29       Impact factor: 19.103

8.  The dilemma of influenza vaccine recommendations when applied to the tropics: the Brazilian case examined under alternative scenarios.

Authors:  Wyller Alencar de Mello; Terezinha Maria de Paiva; Maria Akiko Ishida; Margarete Aparecida Benega; Mirleide Cordeiro Dos Santos; Cécile Viboud; Mark A Miller; Wladimir J Alonso
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

9.  Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial.

Authors:  Eleonora Mutsaerts; Shabir A Madhi; Clare L Cutland; Stephanie Jones; Andrea Hugo; Siobhan Trenor; Florette K Treurnicht; Kerstin Klipstein-Grobusch; Adriana Weinberg; Marta C Nunes
Journal:  Expert Rev Vaccines       Date:  2016-06-06       Impact factor: 5.217

Review 10.  The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy.

Authors:  Paolo Bonanni; Sara Boccalini; Patrizio Zanobini; Nawal Dakka; Chiara Lorini; Francesca Santomauro; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.